LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

Начало・Списък с акции・Kura Oncology Inc

Kura Oncology Inc

Затворен

СекторЗдравеопазване

11.63 -2.1

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

11.5

Максимум

12.19

Ключови измерители
By Trading Economics
Приходи	-8M -74M
Продажби	5.5M 21M
EPS	-0.85
Марж на печалбата	-357.186
Служители	192
EBITDA	-1.3M -74M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+142.68% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	147M 995M
Предишно отваряне	13.73
Предишно затваряне	11.63

Настроения в новините

By Acuity

42%

58%

141 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

5.575 / 6.6 Подкрепа & съпротива

Kura Oncology Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

8.12.2025 г., 23:48 ч. UTC

Значими двигатели на пазара

Shares of Sezzle and Vital Farms Rise on S&P SmallCap 600 Inclusion

8.12.2025 г., 23:44 ч. UTC

Пазарно говорене

Perky Australian Dollar Looks to Extend Gains -- Market Talk

8.12.2025 г., 23:42 ч. UTC

Пазарно говорене

Nikkei May Decline Amid Uncertainty Over Econ, Earnings -- Market Talk

8.12.2025 г., 23:13 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

8.12.2025 г., 23:13 ч. UTC

Пазарно говорене

Australian Inflation Expectations Highest Since Late 2023 -- Market Talk

8.12.2025 г., 23:09 ч. UTC

Придобивния, сливания и поглъщания

Paramount Made a Hostile Bid for Warner After Netflix Deal. What Happens Next? -- WSJ

8.12.2025 г., 22:46 ч. UTC

Пазарно говорене

Rio Tinto Building Low-Cost Lithium Business in Difficult Market -- Market Talk

8.12.2025 г., 22:01 ч. UTC

Пазарно говорене

Miners Poised to Do Well in 2026 -- Market Talk

8.12.2025 г., 22:00 ч. UTC

Придобивния, сливания и поглъщания

Noble: Agreement With Borr Includes Sale of Noble Tom Prosser, Noble Mick O'Brien, Noble Regina Allen, Noble Resilient, Noble Resolute, Closing Expected in Early 2026 >NE

8.12.2025 г., 22:00 ч. UTC

Придобивния, сливания и поглъщания

Noble: Agreement With Borr Comprises $210M in Cash and $150M in Seller Notes >NE

8.12.2025 г., 22:00 ч. UTC

Придобивния, сливания и поглъщания

Noble: Agreement With Ocean Oilfield Drilling Anticipates the Sale of the Noble Resolve, Closing Is Expected in 2Q 2026, Upon Conclusion of Noble Resolve's Current Contract >NE

8.12.2025 г., 22:00 ч. UTC

Придобивния, сливания и поглъщания

Noble: To Sell Five Rigs to Borr Drilling Limited for $360M and One Rig to Ocean Oilfield Drilling for $64M in Cash >NE

8.12.2025 г., 21:51 ч. UTC

Пазарно говорене

US-Canada Rate Spreads Narrow Sharply After Record Gap -- Market Talk

8.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Tech, Media & Telecom Roundup: Market Talk

8.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

8.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

8.12.2025 г., 21:38 ч. UTC

Придобивния, сливания и поглъщания

Boeing Buys Company Responsible for Door Blowout. The Stock Rises. -- Barrons.com

8.12.2025 г., 21:38 ч. UTC

Придобивния, сливания и поглъщания

Paramount Makes $77.9 Billion Hostile Bid for Warner After Netflix Struck Deal -- 7th Update

8.12.2025 г., 21:36 ч. UTC

Пазарно говорене

Oil Oversupply to Show Up As Waterborne Stocks Land -- Market Talk

8.12.2025 г., 21:20 ч. UTC

Придобивния, сливания и поглъщания

Will the Netflix-Warner Bros. Merger Go Through? It Depends on How You Define Market Share. -- Barrons.com

8.12.2025 г., 21:12 ч. UTC

Придобивния, сливания и поглъщания

These Stocks Moved the Most Today: Warner Bros., Paramount, Netflix, Tesla, CoreWeave, Confluent, Marvell, Carvana, and More -- Barrons.com

8.12.2025 г., 21:08 ч. UTC

Пазарно говорене

Rosenberg Turns 'Outright Bullish' on Canada Dollar -- Market Talk

8.12.2025 г., 20:38 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Netflix Co-CEOs Confident About Regulatory Approval for WBD Deal -- Market Talk

8.12.2025 г., 20:26 ч. UTC

Придобивния, сливания и поглъщания

These Stocks Are Moving the Most Today: Warner Bros., Paramount, Netflix, Tesla, CoreWeave, Confluent, Marvell, Carvana, and More -- Barrons.com

8.12.2025 г., 20:18 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Netflix Isn't Looking to Make Cuts at Warner Bros. Discovery -- Market Talk

8.12.2025 г., 20:07 ч. UTC

Пазарно говорене

Oil Futures Snap Three-Session Winning Streak -- Market Talk

8.12.2025 г., 20:06 ч. UTC

Пазарно говорене

U.S. Natural Gas Pulls Back From Weather-Driven Highs -- Market Talk

8.12.2025 г., 20:05 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

8.12.2025 г., 20:05 ч. UTC

Пазарно говорене

Deere Offers Sales Growth Forecast Through 2030 -- Market Talk

8.12.2025 г., 20:01 ч. UTC

Пазарно говорене

Precious Metals Slip Ahead of Fed Decision -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Kura Oncology Inc Прогноза

Ценова цел

By TipRanks

142.68% нагоре

12-месечна прогноза

Среден 29 USD 142.68%

Висок 40 USD

Нисък 16 USD

Според 11 анализатори от Wall Street, предложили 12-месечна ценова цел за Kura Oncology Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

11 ratings

Купи

Задържане

Продай

Според 11 анализатори, дали борсови рейтинги на Kura Oncology Inc през последните 3 месеца.

Техническа оценка

By Trading Central

5.575 / 6.6Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Настроение

By Acuity

141 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.